Mallinckrodt Puts Down $1.3B To Acquire Cadence

Law360, New York (February 11, 2014, 1:25 PM EST) -- Irish specialty pharmaceutical company Mallinckrodt PLC will buy Cadence Pharmaceuticals Inc. for $1.3 billion, the companies said Tuesday, in a deal that nets Mallinckrodt a Cadence portfolio that includes the pain management drug Ofirmev.

Mark Trudeau, CEO and president of Mallinckrodt, said that the purchase of Cadence will help the company achieve the continued growth it desires.

"The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company," Trudeau said in a statement. "Ofirmev's growth is driven by an...
To view the full article, register now.